AI assistant
TherapeuticsMD, Inc. — Director's Dealing 2014
Mar 10, 2014
35134_dirs_2014-03-10_e51f6e2b-1210-486a-897b-2b63bee1af8e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2014-03-10
Reporting Person: Krassan Mitchell (EVP, Chief Strategy Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-03-10 | Common Stock | M | 7500 | $0.1874 | Acquired | 7500 | Direct |
| 2014-03-10 | Common Stock | S | 7500 | $7.732 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-03-10 | Non-Qualified Stock Option (right to buy) | $0.1874 | M | 7500 | Disposed | 2020-05-01 | Common Stock (7500) | Direct |
Footnotes
F1: The shares were sold pursuant to a 10b5-1 Sales Plan dated December 9, 2013.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.64 to $7.81, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.